Merz Pushes Back on US Drug Probe, Citing EU Trade Pact

German Chancellor Friedrich Merz has forcefully rejected a new US tariff investigation into Germany's drug pricing policies, invoking an existing EU trade pact as a bulwark against Washington's claims of 'persistent underpayment' for innovative medicines. This direct pushback comes as the Donald Trump administration escalates its long-running 'America First' campaign, threatening punitive tariffs on German pharmaceutical exports amidst Berlin's own efforts to rein in soaring healthcare spending. The Section 301 investigation, spearheaded by US Trade Representative Jamieson Greer, hinges on the argument that Germany cost-containment measures force American patients to disproportionately shoulder global pharmaceutical Research and Development (R&D) costs. This mirrors the administration's broader Most-Favored-Nation (MFN) drug pricing policy. Notably, major pharmaceutical players like Pfizer, Eli Lilly, and Boehringer Ingelheim have already warned they might scale back investments or delay new drug launches in Germany due to Berlin's proposed healthcare spending reform, which includes deeper discounts from drugmakers. The US has pointed to a recent United Kingdom (UK) pharmaceutical agreement, where London committed to higher payments for innovative drugs in exchange for tariff relief, as a model for Germany to follow. The stakes are high, with a public hearing for the Section 301 investigation slated for September 22, 2026, and written comments due by August 10. The US-EU trade agreement, recently approved by the European Parliament, already caps tariffs on EU industrial goods, including pharmaceuticals, at 15%. This creates a complex diplomatic and economic tightrope, as the outcome will not only redefine transatlantic trade in a critical sector but also test the limits of national sovereignty over healthcare policy versus global trade pressures.